BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 30006330)

  • 21. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
    Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
    EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
    Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
    Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
    Kogame N; Chichareon P; De Wilder K; Takahashi K; Modolo R; Chang CC; Tomaniak M; Komiyama H; Chieffo A; Colombo A; Garg S; Louvard Y; Jüni P; G Steg P; Hamm C; Vranckx P; Valgimigli M; Windecker S; Stoll HP; Onuma Y; Janssens L; Serruys PW
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):100-111. PubMed ID: 31410968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
    Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
    Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Sharma A; Hai O; Garg A; Vallakati A; Lavie CJ; Marmur JD
    Curr Probl Cardiol; 2017 Dec; 42(12):404-417. PubMed ID: 29110813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation.
    Collet JP; Silvain J; Kerneis M; Cuisset T; Meneveau N; Boueri Z; Barthélémy O; Rangé G; Cayla G; Belle EV; Elhadad S; Carrié D; Caussin C; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
    Clin Cardiol; 2016 Apr; 39(4):192-200. PubMed ID: 26880570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
    Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.